{"name":"Palvella Therapeutics, Inc.","slug":"palvella-therapeutics-inc","ticker":"","exchange":"","domain":"palvella.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PTX-022","genericName":"PTX-022","slug":"ptx-022","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"QTORIN 3.9% rapamycin anhydrous gel","genericName":"QTORIN 3.9% rapamycin anhydrous gel","slug":"qtorin-3-9-rapamycin-anhydrous-gel","indication":"Moderate to severe atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"PTX-022","genericName":"PTX-022","slug":"ptx-022","phase":"phase_3","mechanism":"PTX-022 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) designed to modulate immune cell function and tumor microenvironment.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"QTORIN 3.9% rapamycin anhydrous gel","genericName":"QTORIN 3.9% rapamycin anhydrous gel","slug":"qtorin-3-9-rapamycin-anhydrous-gel","phase":"phase_3","mechanism":"QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOWmhWQWdtd0Z0RG8xU0UwX0wyQ3BVU29TeTg1UXVBcDZCUTRrZWs1V2pydjZ2SEoyWEhaSi05ODNCNVJ4bXNzbzhOUzhLcW1lOWk0Qm1JS2dna3BLbVpiaGNQMzlyUmRDTmhQZ0M2SGhlZHQtN1hvbTNLc2FDRjNId3c4ZHE4Y3VQMzEtMXhLRGowaklpVXRFMmZKUnl1M0V3Zkxtb2tOb0hHb1o4eEl4d2k0Smc?oc=5","date":"2026-04-07","type":"trial","source":"Stock Titan","summary":"Palvella (NASDAQ: PVLA) shows pivotal rare-disease data and $274M cash runway - Stock Titan","headline":"Palvella (NASDAQ: PVLA) shows pivotal rare-disease data and $274M cash runway","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4wbVBZSmZva2E2T091bGRHdUlReXF5MXVZdWFFZndNX1U4STVROU11ZkFhZ1JSb3pFTTl1UFBQY0dMSWttODBiZDVIbHUtcjRvb2xWdWE0TUNUUTNlOXlN?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill","headline":"PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPMUljUWpVSlE5aHRXbzBGNGdZSWdHVXVySVczb3Y4Zm9mUlloTGFNVjd6dFVrWktRTHkwYmNvSnZsNG10ZUxvV3RmODhOaU1Cd2VQaUJsczlhWTVmdTJJSXpEZW1DQS1GTXNsTS1CQm9kb1FiUm9rTTF1QjZlLWJ4QW9zWjM3ZEdiRkJuU2NBYWhzUkxyM0tWNWF4NWtENTNkemsySW1GTGQzTktMSmlpOVJjVFh6dUNtbXIwRWNDYnlGa0RCZkNGVmlmdFUyMEZ1SzFPZFM4TVdGTlliVUMzRlNqNlp4VlpDeGZwS0x5SQ?oc=5","date":"2026-03-31","type":"pipeline","source":"minichart.com.sg","summary":"Palvella Therapeutics QTORIN Rapamycin: Novel Treatment Advancements for Rare Skin Diseases and Vascular Malformations - minichart.com.sg","headline":"Palvella Therapeutics QTORIN Rapamycin: Novel Treatment Advancements for Rare Skin Diseases and Vascular Malformations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQckNZT0Fja1VJb2pOcGlFSERDVGtyV0hiaVVvd1RyY1RNdWp3aGxVUXhDUWlyQlExLTRqanhLMTc2TkVLYkU5VGlhY2l2UjJfMWpDeDJ6SWhURk1GYjBkb0VCSFJlakdWNjRROTFvcnBmZjhzelVGbVFRNGZsSXYxMmV0ZGJsQWdvOXZlRjEzaUZOMjNYLWU2eXJhM2lYeTd3YTFCTzVRdWhpTkgtSFgxVENwZmx5bERTSUx0a2stNDRiajRqSlZWOWhGWm5tanJYaG83WU12WUFkTmpOdDVIQTdiWGJhcm03OHRMT0ZOYTJqa2lFLVJaaXpoLWZhMFBoNC1pOFVSRlJ0emc?oc=5","date":"2026-03-25","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxONU1hN09Lblc1VVdSZ0dnbkdTYlB6Y21ZWnEyUnFfak5qRXZfQnlQeVpxMU1QWTlEMzZpaVZHSTd3OEdqNGtGU3lLU0J2dXNLTE80a1BMcm5HVE5ybkJ1eklwZ194SWVWdFI5UV9TTnA0SUswTElSalZZX0ZQMjdJMG5Gb1JIUnJYWFE?oc=5","date":"2026-03-18","type":"trial","source":"Manufacturing Chemist","summary":"Palvella's QTORIN achieves positive Phase III results - Manufacturing Chemist","headline":"Palvella's QTORIN achieves positive Phase III results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE8td0NOWnAxWGxyQmowRGVxWEs2akxVMFNLS0JrZVVUUVBCek1Vekc1RnZqWmhWaFNDS0xrWm9kdXdDTks3SFBuN2RBVDBVSVNzb2FsV2RvUU5sTlEyWG1IVFljeWRMeGJTZkk1U29JNkE2SGpXRVdQWU1B?oc=5","date":"2026-03-02","type":"trial","source":"VISTA.Today","summary":"Wayne-Based Palvella Shares Soar as Lead Drug Candidate Meets Trial Goals - VISTA.Today","headline":"Wayne-Based Palvella Shares Soar as Lead Drug Candidate Meets Trial Goals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNbHhLSFViQ2lKWF9rVUl2eWJ6eDlQUEN6bG1HVmloaGFKRWxqTW9uNnJ1cDNpVlIzdmpUYmdoU3BWN1l2Z0cyOXpCcVAtemktdEp2c2s3ZDFHR2QxZHZ6RnZZRko2LUVRY1lPOHpobzg5bFB4X3g2SnRGbWt3Vk9DTW55M3VaN2xDbEFXVEFUak1ZVGNsbGdGX2ZLM1E0YzhaZ2xudHZJUUVqNTYza1g3SzBOcDZfZm14ZEFJVDc2MU1Tc3cxdjlCNnEtcXVWcWE3Rl82YURLS2tkSVN4ekpWNHJRaEppSkFBUFRxb1RlbURWNXRTa2dGTzFGSDAzb2lqdFRPeHIxTEVUY2h2OC1NaGsyc2lYSnIyMG5JVzNkaXRwM2xJRlF2bXpFYlVqd3pfT0lzRGp1dWhTTVhFdzFBRGNkQXNvV1NaSmo2Y0I0THFyMkxLN3c?oc=5","date":"2026-01-07","type":"pipeline","source":"GlobeNewswire","summary":"Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire","headline":"Palvella Therapeutics Strengthens Leadership Team with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFB4VnVER21RQ1lqUExOTk9jUzFRVUpSSjUxVG5DenlvUGFJTHlYem94azExb0xZLVp3V0p1WWtrTUFkZlBUcVc0UkFpNVJtbE52aEx0eUhtdVk0ZTJOWC1yWmw0MUNqd2Rrd255UjloQ2lSNTBvTElzUTJINA?oc=5","date":"2025-11-24","type":"pipeline","source":"Yahoo Finance","summary":"The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance","headline":"The Short-Sellers May Be Right About This Red-Hot Pharma Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE42dEJXU0FEa013VzVWdDh4VGhIZVVOd3NpUnJIV2ZsVW9WaTUxWXctXzNRXzFwTXNNbHE5LU1xb2tScUZCV25SWlEyNjA2dUs3MjZNVElMQWlidm5UbUhlNzNpb1FKZWZ3ZzRUelJ3?oc=5","date":"2025-09-11","type":"pipeline","source":"MarketBeat","summary":"Palvella Therapeutics (PVLA) Short Interest & Short Float | Updated Apr 2026 - MarketBeat","headline":"Palvella Therapeutics (PVLA) Short Interest & Short Float | Updated Apr 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-30","type":"pipeline","source":"simplywall.st","summary":"A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st","headline":"A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPcmY4TUhzYlFMNkY4aWZ0cEk4dlBvTTkxbmRQeWRNa0dDWlAtMzN5UjdSWmFrSnZVUVBMdVdPTGJ1d1hlWVpfM2JZaVhmQWd2cTBiaXdUaEJ3eEpsLW1SejcxVmNlc0VWQlJXQ3pubkMtVEFSVGY1S2Q4eUdQeGZXa01pbW9fUnEyWGVqRE52MzBka0wzYnY0dlJMVmV4cWJvdVQwREdWaEdBQzZmU1JyWERyU1Q4eHF3VUZKdTVJZG9DVnlDSzlBc3pvSkJBWXZqLVM5TktBYzA3S0d4dVpKVmdqaDFYcGQzd3ZMZU5xbUFQQzJweUNKcUh5Mi1CeVllalNIMTJDcVd6SzlaT0w1WGlhZnNISUJIb2FqdzV5c2d5WXNLMDJkQ0h0Z0FXa2JqWU4zUXFYd040bjRRU0N4LTl3Y3VmUDQ?oc=5","date":"2025-05-27","type":"pipeline","source":"GlobeNewswire","summary":"Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire","headline":"Palvella Therapeutics Strengthens Executive Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxON3pkYlVqeVA0d3ZNbGxwYlY0NDg1Nk15b1lLS1VIZzI5X3EyV2pFZC0wZUNPemZPRjNMQnpxQlMtdFFaOFVSUFcwdXplemsyNUhSTW9GcmZ4cWh3aGI0QXJkUGtjUDdZdTVGVGxSLU40dS1oX0ZsMlMyYmF6bU1Xcjg5czhzUHc?oc=5","date":"2025-03-01","type":"pipeline","source":"Yahoo Finance","summary":"Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 - Yahoo Finance","headline":"Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}